HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

The agreement includes pre-payment commitments for product sales and distribution of HCW11-006, a second-generation multi-cytokine-based product intended for use as a reagent. The arrangement provides commercial validation and potential near-term revenue visibility, although no financial terms, volumes, or counterparties were disclosed.